![Image](https://m.media-amazon.com/images/M/MV5BOGZiZTlkOWEtNjQ4NS00MWU3LWJmYjYtOTMxZDlkZmE2MjM1XkEyXkFqcGdeQXVyMTE0MzQwMjgz._V1_QL75_UY140_CR55,0,140,140_.jpg)
![Image](https://m.media-amazon.com/images/M/MV5BOGZiZTlkOWEtNjQ4NS00MWU3LWJmYjYtOTMxZDlkZmE2MjM1XkEyXkFqcGdeQXVyMTE0MzQwMjgz._V1_QL75_UY140_CR55,0,140,140_.jpg)
New York, June 19 (Ians) An experimental stem cell therapy has reduced seizure frequency by almost 95 per cent in the first two epilepsy patients, according to early results of a trial. Developed by San Francisco-based biotech Neurona Therapeutics, the single dose therapy, called Nrtx-1001, involves lab-grown neurons which are injected in the patients to silence the seizure activity in the epileptic region of the brain.
The regenerative neural cell therapy, Nrtx-1001, was derived from human pluripotent stem cells.
The preliminary data demonstrate promising reduction (90 per cent) in seizure frequency in the first and second patients at one year and seven-months post-treatment, respectively. In addition, neuropsychological testing suggests an improvement in memory after Nrtx-1001 administration.
“Although our clinical investigation is ongoing in additional patients, it is gratifying to witness the first two patients achieving seizure relief without additional cognitive impairment to date,” said Cory Nicholas, the CEO of Neurona Therapeutics, in a statement.
The regenerative neural cell therapy, Nrtx-1001, was derived from human pluripotent stem cells.
The preliminary data demonstrate promising reduction (90 per cent) in seizure frequency in the first and second patients at one year and seven-months post-treatment, respectively. In addition, neuropsychological testing suggests an improvement in memory after Nrtx-1001 administration.
“Although our clinical investigation is ongoing in additional patients, it is gratifying to witness the first two patients achieving seizure relief without additional cognitive impairment to date,” said Cory Nicholas, the CEO of Neurona Therapeutics, in a statement.
- 6/19/2023
- by Agency News Desk
- GlamSham
IMDb.com, Inc. takes no responsibility for the content or accuracy of the above news articles, Tweets, or blog posts. This content is published for the entertainment of our users only. The news articles, Tweets, and blog posts do not represent IMDb's opinions nor can we guarantee that the reporting therein is completely factual. Please visit the source responsible for the item in question to report any concerns you may have regarding content or accuracy.